witnessed notable market growth since the NHS concentrates on the development of innovative treatments for chronic diseases, the use of GLP-1 for the treatment of diabetes, and its relatively recent adoption of GLP-1 drugs in weight management
Short-chain fatty acids (SCFAs)produced by fermentation of dietary fiberaffect BCAA metabolic gene expression through epigenetic mechanisms and stimulate GLP-1 release from intestinal L cells (132)
doi: 10.3389/fcimb.2024.1325500 Received 21 October 2023 Accepted 05 January 2024 Published 25 January 2024 Volume 14 - 2024 Edited by Adwoa Asanta-Poku, University of Ghana, Ghana Reviewed by Keda Chen, Zhejiang Shuren University, China Updates Copyright 2024 Zhang, Ma, Zhang, Ma, Wang, Yang, Jia, Wu and Wang
Its about something almost no one in rheumatology is publicly discussing yet microdosing GLP-1 medications for psoriatic arthritis